ICO 007
Alternative Names: ICO-007; ISIS-13650Latest Information Update: 13 Sep 2024
At a glance
- Originator Isis Pharmaceuticals
- Developer Breakthrough T1D; iCo Therapeutics
- Class Antisense oligonucleotides; Eye disorder therapies
- Mechanism of Action Proto oncogene protein c raf inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Discontinued Age-related macular degeneration; Diabetic macular oedema
Most Recent Events
- 28 Nov 2014 ICO 007 is available for licensing as of 28 Nov 2014. www.icotherapeutics.com/
- 28 Nov 2014 Discontinued - Phase-II for Diabetic macular oedema in USA (Intravitreous)
- 28 Nov 2014 Discontinued - Preclinical for Age-related macular degeneration in USA (Intravitreous)